Bleomycin omission in limited-stage classic Hodgkin lymphoma with negative PET scan after two cycles of ABVD

Authors

Institutions

Publication Details

Journal
Haematologica
Published
2026-03-05
DOI
https://doi.org/10.3324/haematol.2025.289285
Primary Topic
Lymphoma Diagnosis and Treatment
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Bleomycin omission in limited-stage classic Hodgkin lymphoma with negative PET scan after two cycles of ABVD

Christopher P. Venner, Alina S. Gerrie, François Bénard, Andrea Lo et al.
Haematologica
Lymphoma Diagnosis and Treatment
article

Bleomycin omission in limited-stage classic Hodgkin lymphoma with negative PET scan after two cycles of ABVD

Christopher P. Venner, Alina S. Gerrie, François Bénard, Andrea Lo, Jiayu Yang, Diego Villa, Laurie H. Sehn, David W. Scott, Don C. Wilson, R. Petter Tonseth, Kerry J. Savage
article en

Abstract

No abstract available for this paper.
Haematologica
BC Cancer Agency (CA), University of British Columbia (CA), Spinal Cord Injury BC (CA)
Bristol-Myers Squibb, AstraZeneca, Gilead Sciences, Teva Pharmaceutical Industries, Celgene, Regeneron Pharmaceuticals, BeiGene, Seagen, Genentech
Zero hunger
Openalex Percentile: Top 34%
Lymphoma Diagnosis and Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.